Bristol Myers Squibb (BMY) and Gilead Sciences (GILD) are major biotech companies with distinct strengths. BMY excels in oncology and emerging therapies, driven by products like Opdivo and Reblozyl, while facing challenges from generic competition for legacy products. Its aggressive growth strategy includes acquisitions, but it has elevated financial risks with a high debt ratio. GILD leads in HIV treatment through successful products like Biktarvy and Descovy, with promising new therapies like Yeztugo. GILD’s financial health is slightly stronger, with better stock performance this year and a higher dividend yield. However, BMY offers a more attractive valuation and robust growth potential, making it the more compelling pick currently despite recent stock declines.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.tradingview.com/news/zacks:570b790a6094b:0-bristol-myers-vs-gilead-sciences-which-biotech-stock-is-a-better-bet-now/
